个人中心 - 老虎社区

tzm88

IP属地：未知

帖子 · 299帖子 · 299
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- tzm88tzm88
  ·2021-12-30
  Ok
  Semiconductor Stocks Mixed in Morning Trading<blockquote>半导体股早盘涨跌互现</blockquote>
  Semiconductor stocks mixed in morning trading.Micron Technology jumped nearly 3% while Nvidia and AM
  Semiconductor Stocks Mixed in Morning Trading<blockquote>半导体股早盘涨跌互现</blockquote>
  2,051 评论
  4
  分享
  举报
- tzm88tzm88
  ·2021-12-29
  Ok
  Some Gaming Stocks Gained in Morning Trading<blockquote>部分游戏股早盘上涨</blockquote>
  Some gaming stocks gained in morning trading.Activision Blizzard, Playtika Holding, Zynga and Electr
  Some Gaming Stocks Gained in Morning Trading<blockquote>部分游戏股早盘上涨</blockquote>
  2,540 评论
  4
  分享
  举报
- tzm88tzm88
  ·2021-12-28
  Like
  非常抱歉，此主贴已删除
  2,918 1
  5
  分享
  举报
- tzm88tzm88
  ·2021-12-27
  Ok
  非常抱歉，此主贴已删除
  2,972 评论
  6
  分享
  举报
- tzm88tzm88
  ·2021-12-26
  Ok
  非常抱歉，此主贴已删除
  3,140 1
  4
  分享
  举报
- tzm88tzm88
  ·2021-12-25
  Ok
  非常抱歉，此主贴已删除
  2,850 评论
  4
  分享
  举报
- tzm88tzm88
  ·2021-12-24
  Ok
  U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸列为第二种易于使用的抗 COVID-19 药物</blockquote>
  U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea
  U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸列为第二种易于使用的抗 COVID-19 药物</blockquote>
  2,555 评论
  5
  分享
  举报
- tzm88tzm88
  ·2021-12-23
  Ok
  Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么 Paychex 股价今天创下历史新高</blockquote>
  Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco
  Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么 Paychex 股价今天创下历史新高</blockquote>
  2,615 1
  3
  分享
  举报
- tzm88tzm88
  ·2021-12-22
  Great ariticle, would you like to share it?
  非常抱歉，此主贴已删除
  1,895 1
  3
  分享
  举报
- tzm88tzm88
  ·2021-12-21
  Ok
  非常抱歉，此主贴已删除
  2,561 评论
  5
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3576964422127394","uuid":"3576964422127394","gmtCreate":1613870398181,"gmtModify":1639620895262,"name":"tzm88","pinyin":"tzm88","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":22,"headSize":631,"tweetSize":299,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":6,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.08.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.10","exceedPercentage":"80.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.29","exceedPercentage":"80.48%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692073118,"gmtCreate":1640817348369,"gmtModify":1640817348594,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692073118","repostId":"1149988860","repostType":4,"repost":{"id":"1149988860","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640792807,"share":"https://www.laohunote.com/m/news/1149988860?lang=zh_CN&edition=full","pubTime":"2021-12-29 23:46","market":"us","language":"en","title":"Semiconductor Stocks Mixed in Morning Trading<blockquote>半导体股早盘涨跌互现</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149988860","media":"Tiger Newspress","summary":"Semiconductor stocks mixed in morning trading.Micron Technology jumped nearly 3% while Nvidia and AM","content":"<p><html><head></head><body>Semiconductor stocks mixed in morning trading.Micron Technology jumped nearly 3% while Nvidia and AMD fell more than 2%.</p><p><blockquote><html><head></head><body>半导体股早盘涨跌互现。美光科技上涨近3%，英伟达和AMD下跌超过2%。</body></html></blockquote></p><p><img src=\"https://static.tigerbbs.com/f4d9932e27e7be43b2a47e9900754cd6\" tg-width=\"412\" tg-height=\"177\" width=\"100%\" height=\"auto\"/></p><p><blockquote></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Semiconductor Stocks Mixed in Morning Trading<blockquote>半导体股早盘涨跌互现</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSemiconductor Stocks Mixed in Morning Trading<blockquote>半导体股早盘涨跌互现</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-29 23:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Semiconductor stocks mixed in morning trading.Micron Technology jumped nearly 3% while Nvidia and AMD fell more than 2%.</p><p><blockquote><html><head></head><body>半导体股早盘涨跌互现。美光科技上涨近3%，英伟达和AMD下跌超过2%。</body></html></blockquote></p><p><img src=\"https://static.tigerbbs.com/f4d9932e27e7be43b2a47e9900754cd6\" tg-width=\"412\" tg-height=\"177\" width=\"100%\" height=\"auto\"/></p><p><blockquote></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","MU":"美光科技","AMD":"美国超微公司"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149988860","content_text":"Semiconductor stocks mixed in morning trading.Micron Technology jumped nearly 3% while Nvidia and AMD fell more than 2%.","news_type":1,"symbols_score_info":{"NVDA":0.9,"AMD":0.9,"MU":0.9}},"isVote":1,"tweetType":1,"viewCount":2051,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696536787,"gmtCreate":1640732378572,"gmtModify":1640732378840,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696536787","repostId":"1149345512","repostType":4,"repost":{"id":"1149345512","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640705349,"share":"https://www.laohunote.com/m/news/1149345512?lang=zh_CN&edition=full","pubTime":"2021-12-28 23:29","market":"us","language":"en","title":"Some Gaming Stocks Gained in Morning Trading<blockquote>部分游戏股早盘上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149345512","media":"Tiger Newspress","summary":"Some gaming stocks gained in morning trading.Activision Blizzard, Playtika Holding, Zynga and Electr","content":"<p>Some gaming stocks gained in morning trading.Activision Blizzard,&nbsp;Playtika Holding,&nbsp;Zynga&nbsp;and&nbsp;Electronic Arts&nbsp;climbed between 1% and 3%.</p><p><blockquote>一些游戏股在早盘交易中上涨。动视暴雪、Playtika Holding、Zynga 和艺电股价上涨 1% 至 3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/eaefc8e1edf986edb1747eb2ba57c451\" tg-width=\"425\" tg-height=\"358\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Gaming Stocks Gained in Morning Trading<blockquote>部分游戏股早盘上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Gaming Stocks Gained in Morning Trading<blockquote>部分游戏股早盘上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-28 23:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some gaming stocks gained in morning trading.Activision Blizzard,&nbsp;Playtika Holding,&nbsp;Zynga&nbsp;and&nbsp;Electronic Arts&nbsp;climbed between 1% and 3%.</p><p><blockquote>一些游戏股在早盘交易中上涨。动视暴雪、Playtika Holding、Zynga 和艺电股价上涨 1% 至 3%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/eaefc8e1edf986edb1747eb2ba57c451\" tg-width=\"425\" tg-height=\"358\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149345512","content_text":"Some gaming stocks gained in morning trading.Activision Blizzard, Playtika Holding, Zynga and Electronic Arts climbed between 1% and 3%.","news_type":1,"symbols_score_info":{"ATVI":0.9}},"isVote":1,"tweetType":1,"viewCount":2540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696111737,"gmtCreate":1640649131901,"gmtModify":1640649170350,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696111737","repostId":"1127544468","repostType":4,"isVote":1,"tweetType":1,"viewCount":2918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698782775,"gmtCreate":1640558523127,"gmtModify":1640558523406,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698782775","repostId":"2193178197","repostType":4,"isVote":1,"tweetType":1,"viewCount":2972,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698564582,"gmtCreate":1640470346669,"gmtModify":1640470346936,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698564582","repostId":"2193317305","repostType":4,"isVote":1,"tweetType":1,"viewCount":3140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698663983,"gmtCreate":1640385057750,"gmtModify":1640385058028,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698663983","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":2850,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698944082,"gmtCreate":1640296163347,"gmtModify":1640296164369,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698944082","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","kind":"news","pubTimestamp":1640269891,"share":"https://www.laohunote.com/m/news/1192623075?lang=zh_CN&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸列为第二种易于使用的抗 COVID-19 药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对 COVID-19 的药丸，为对抗奥密克戎感染的上升浪潮提供了另一种易于使用的药物。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>在美国食品和药物管理局批准默克公司的莫努匹拉韦的前一天，该机构批准了辉瑞公司的一种竞争药物。这种名为 Paxlovid 的药丸很可能成为对抗病毒的首选治疗方法，这要归功于其卓越的益处和较轻的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药丸预计在对抗大流行病方面的作用将小于几周前的预测。它阻止严重 COVID-19 的能力比最初宣布的要小得多，而且药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于出现 COVID-19 早期症状、住院风险最高的成年人，包括老年人和患有肥胖症和心脏病等疾病的人。英国于 11 月初首次批准了这种药丸。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有怀孕期间禁止使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后的几天内使用避孕措施，而男性应在最后一剂后至少三个月内使用避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA 顾问小组上个月仅以微弱优势批准了该药物，并警告说，该药物的使用必须严格针对最能受益的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞公司的药丸作用不同，风险也不同。此外，辉瑞公司的药物在检测中的有效性约为三倍，将高危患者的住院和死亡率降低了近 90%，而默克公司的住院和死亡率降低了 30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>“梅奥诊所的格雷戈里-波兰（Gregory Poland）博士在谈到默克公司的药物时说：”只要辉瑞公司的药片供应充足，我认为它就不会被使用。“没有理由这样做，因为它的疗效较差，副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA 的决定为对抗这种已导致超过 80 万美国人死亡的病毒提供了另一个潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录的病例、住院和死亡做好准备。包括默克公司在内的抗病毒药丸有望对奥密克戎病毒有效，因为它们不针对刺突蛋白，而刺突蛋白是该变种病毒大部分令人担忧的突变所在。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA 的决定是基于结果显示，近 7% 服用该药物的患者最终住院，一名患者在 30 天后死亡。相比之下，10%的住院患者服用安慰剂，9人死亡。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已经同意购买足够的药物来治疗310万人。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约 700 美元，该疗程要求患者每天服用两次，每次四片，连续服用五天。哈佛大学和伦敦国王学院的一项审查估计，每个 40 粒疗程的治疗费用约为 18 美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖速度。这种遗传效应引发了人们的担忧，即这种药物可能会导致人类胎儿发生突变，甚至刺激更具毒性的病毒株。但FDA科学家表示，变异风险在很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸列为第二种易于使用的抗 COVID-19 药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸列为第二种易于使用的抗 COVID-19 药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">SeattleTimes</strong><span class=\"h-time small\">2021-12-23 22:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对 COVID-19 的药丸，为对抗奥密克戎感染的上升浪潮提供了另一种易于使用的药物。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>在美国食品和药物管理局批准默克公司的莫努匹拉韦的前一天，该机构批准了辉瑞公司的一种竞争药物。这种名为 Paxlovid 的药丸很可能成为对抗病毒的首选治疗方法，这要归功于其卓越的益处和较轻的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药丸预计在对抗大流行病方面的作用将小于几周前的预测。它阻止严重 COVID-19 的能力比最初宣布的要小得多，而且药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于出现 COVID-19 早期症状、住院风险最高的成年人，包括老年人和患有肥胖症和心脏病等疾病的人。英国于 11 月初首次批准了这种药丸。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有怀孕期间禁止使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后的几天内使用避孕措施，而男性应在最后一剂后至少三个月内使用避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA 顾问小组上个月仅以微弱优势批准了该药物，并警告说，该药物的使用必须严格针对最能受益的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞公司的药丸作用不同，风险也不同。此外，辉瑞公司的药物在检测中的有效性约为三倍，将高危患者的住院和死亡率降低了近 90%，而默克公司的住院和死亡率降低了 30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>“梅奥诊所的格雷戈里-波兰（Gregory Poland）博士在谈到默克公司的药物时说：”只要辉瑞公司的药片供应充足，我认为它就不会被使用。“没有理由这样做，因为它的疗效较差，副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA 的决定为对抗这种已导致超过 80 万美国人死亡的病毒提供了另一个潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录的病例、住院和死亡做好准备。包括默克公司在内的抗病毒药丸有望对奥密克戎病毒有效，因为它们不针对刺突蛋白，而刺突蛋白是该变种病毒大部分令人担忧的突变所在。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA 的决定是基于结果显示，近 7% 服用该药物的患者最终住院，一名患者在 30 天后死亡。相比之下，10%的住院患者服用安慰剂，9人死亡。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已经同意购买足够的药物来治疗310万人。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约 700 美元，该疗程要求患者每天服用两次，每次四片，连续服用五天。哈佛大学和伦敦国王学院的一项审查估计，每个 40 粒疗程的治疗费用约为 18 美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖速度。这种遗传效应引发了人们的担忧，即这种药物可能会导致人类胎儿发生突变，甚至刺激更具毒性的病毒株。但FDA科学家表示，变异风险在很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">SeattleTimes</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1,"symbols_score_info":{"MRK":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691269785,"gmtCreate":1640208842951,"gmtModify":1640208843182,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691269785","repostId":"1169752126","repostType":4,"repost":{"id":"1169752126","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640186708,"share":"https://www.laohunote.com/m/news/1169752126?lang=zh_CN&edition=full","pubTime":"2021-12-22 23:25","market":"us","language":"en","title":"Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么 Paychex 股价今天创下历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169752126","media":"Benzinga Earnings","summary":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal seco","content":"<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>该公司公布好于预期的 2022 年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex 报告季度调整后每股收益为 91 美分，超出了每股 80 美分的预期。该公司公布季度收入为 11.1 亿美元，超出预期的 10.6 亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex 表示，预计 2022 财年收入增长 10% 至 11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了 2022 财年第二季度强劲的财务业绩，总收入增长 13%，稀释每股收益增长 21%。业绩得益于客户群员工的增长以及持续强劲的销售增长和客户保留率，”他说<b>马丁·穆奇</b>Paychex 董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex 在 52 周内的交易价格低至 85.30 美元。在周三的交易时段，它创下了 52 周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨 5.54%，至 133.44 美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么 Paychex 股价今天创下历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Paychex Shares Are Making New All-Time Highs Today<blockquote>为什么 Paychex 股价今天创下历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-12-22 23:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Paychex Inc</b>&nbsp;is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.</p><p><blockquote><b>Paychex公司</b>该公司公布好于预期的 2022 年第二季度财务业绩后，周三股价走高。</blockquote></p><p> Paychex reported quarterly adjusted&nbsp;earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.</p><p><blockquote>Paychex 报告季度调整后每股收益为 91 美分，超出了每股 80 美分的预期。该公司公布季度收入为 11.1 亿美元，超出预期的 10.6 亿美元。</blockquote></p><p> Paychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.</p><p><blockquote>Paychex 表示，预计 2022 财年收入增长 10% 至 11%。</blockquote></p><p> \"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said&nbsp;<b>Martin Mucci</b>, chairman and CEO of Paychex.</p><p><blockquote>“我们公布了 2022 财年第二季度强劲的财务业绩，总收入增长 13%，稀释每股收益增长 21%。业绩得益于客户群员工的增长以及持续强劲的销售增长和客户保留率，”他说<b>马丁·穆奇</b>Paychex 董事长兼首席执行官。</blockquote></p><p> Paychex is a leading provider of payroll, human capital management&nbsp;and insurance solutions servicing small and midsize clients primarily in the United States.</p><p><blockquote>Paychex是一家领先的薪资、人力资本管理和保险解决方案提供商，主要为美国的中小型客户提供服务。</blockquote></p><p> <b>PAYX Price Action:</b>Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.</p><p><blockquote><b>PAYX价格走势：</b>Paychex 在 52 周内的交易价格低至 85.30 美元。在周三的交易时段，它创下了 52 周新高。</blockquote></p><p> The stock was up 5.54% at $133.44.</p><p><blockquote>该股上涨 5.54%，至 133.44 美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYX":"沛齐"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169752126","content_text":"Paychex Inc is trading higher Wednesday after the company announced better-than-expected fiscal second-quarter 2022 financial results.\nPaychex reported quarterly adjusted earnings of 91 cents per share, which beat the estimate of 80 cents per share. The company reported quarterly revenue of $1.11 billion, which beat the estimate of $1.06 billion.\nPaychex said it expects fiscal-year 2022 revenue growth of 10% to 11%.\n\"We posted strong financial results for the second quarter of fiscal 2022, with growth of 13% in total revenue and 21% in diluted earnings per share. Results were driven by growth in employees within our client base and continued strong sales growth and client retention,\" said Martin Mucci, chairman and CEO of Paychex.\nPaychex is a leading provider of payroll, human capital management and insurance solutions servicing small and midsize clients primarily in the United States.\nPAYX Price Action:Paychex has traded as low as $85.30 over a 52-week period. It's making new 52-week highs during Wednesday's trading session.\nThe stock was up 5.54% at $133.44.","news_type":1,"symbols_score_info":{"PAYX":0.9}},"isVote":1,"tweetType":1,"viewCount":2615,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691910749,"gmtCreate":1640121823087,"gmtModify":1640121823348,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691910749","repostId":"1131687838","repostType":4,"isVote":1,"tweetType":1,"viewCount":1895,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693262832,"gmtCreate":1640042341995,"gmtModify":1640042342230,"author":{"id":"3576964422127394","authorId":"3576964422127394","name":"tzm88","avatar":"https://static.tigerbbs.com/048b92e06af83dad658ad6f664653f04","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3576964422127394","idStr":"3576964422127394"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693262832","repostId":"2193761136","repostType":4,"isVote":1,"tweetType":1,"viewCount":2561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}